Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?

Purpose. The purpose of this study is to investigate the use of PET/CT with fluorodeoxyglucose (FDG), fluorothymidine (FLT) and fluoromisonidazole (FMISO) for radiotherapy (RT) target definition and evolution in rectal cancer. Materials and methods. PET/CT was performed before and during preoperative chemoradiotherapy (CRT) in 15 patients with resectable rectal cancer. PET signals were delineated and CT images on the different time points were non-rigidly registered. Mismatch analyses were carried out to quantify the overlap between FDG and FLT or FMISO tumour volumes (TV) and between PET TVs over time. Results. Ninety sequential PET/CT images were analyzed. The mean FDG, FLT and FMISO-PET TVs showed a tendency to shrink during preoperative CRT. On each time point, the mean FDG-PET TV was significantly larger than the FMISO-PET TV but not significantly larger than the mean FLT-PET TV. There was a mean 65% mismatch between the FMISO and FDG TVs obtained before and during CRT. FLT TVs corresponded better with the FDG TVs (25% mismatch before and 56% during CRT). During CRT, on average 61% of the mean FDG TV (7 cc) overlapped with the baseline mean TV (15.5 cc) (n=15). For FLT, the TV overlap was 49% (n=5) and for FMISO only 20% of the TV during CRT remained inside the contour at baseline (n=10). Conclusion. FDG, FLT and FMISO-PET reflect different functional characteristics that change during CRT in rectal cancer. FLT and FDG show good spatial correspondence, while FMISO seems less reliable due to the non-specific FMISO uptake in normoxic tissue and tracer diffusion through the bowel wall. FDG and FLT-PET/CT imaging seem most appropriate to integrate in preoperative RT for rectal cancer.

[1]  H. Hoekstra,et al.  [18F]FLT-PET in oncology: current status and opportunities , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Gig Mageras,et al.  Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[3]  H. Dittmann,et al.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Anne Bol,et al.  Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  S. Loi,et al.  Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial , 2005, British Journal of Cancer.

[6]  J. Fleshman,et al.  A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. , 2001, International journal of radiation oncology, biology, physics.

[7]  D. Visvikis,et al.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  A. Chan,et al.  Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. , 2000, International journal of radiation oncology, biology, physics.

[9]  S. Ametamey,et al.  Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[11]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Sadek Nehmeh,et al.  The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. , 2008, International journal of radiation oncology, biology, physics.

[13]  Roland Bares,et al.  Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[16]  Cesare Guida,et al.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  S. Taylor Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[18]  Daniela Thorwarth,et al.  Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  J. Balter,et al.  Imaging and alignment for image-guided radiation therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Sanjiv S. Gambhir,et al.  Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer , 2007, Technology in cancer research & treatment.

[21]  Anne Bol,et al.  A gradient-based method for segmenting FDG-PET images: methodology and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  V. Grégoire,et al.  Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. , 2006, Seminars in radiation oncology.

[23]  Roland Bares,et al.  Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer , 2007 .

[24]  A. Hanlon,et al.  Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. , 1998, International journal of radiation oncology, biology, physics.

[25]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[27]  Frederik Maes,et al.  Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. , 2009, International journal of radiation oncology, biology, physics.

[28]  L. Dubois,et al.  Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry , 2004, British Journal of Cancer.

[29]  W. Oyen,et al.  18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients , 2007, Journal of Nuclear Medicine.

[30]  Torsten Rohlfing,et al.  Volume-preserving nonrigid registration of MR breast images using free-form deformation with an incompressibility constraint , 2003, IEEE Transactions on Medical Imaging.

[31]  Daniel Rueckert,et al.  Nonrigid registration using free-form deformations: application to breast MR images , 1999, IEEE Transactions on Medical Imaging.

[32]  Lei Xing,et al.  Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution. , 2005, Medical physics.